Involvement of platelet-derived growth factor in disease: development of specific antagonists.
about
Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targetsCCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFRβ in colorectal carcinomaCardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress.Effects of the tyrosine protein kinase inhibitor genistein on the proliferation, activation of cultured rat hepatic stellate cells.Nucleic acid aptamers in cancer medicine.Nanofibrous scaffolds incorporating PDGF-BB microspheres induce chemokine expression and tissue neogenesis in vivo.Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse modelBiologic effects of platelet-derived growth factor receptor α blockade in uterine cancer.Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.Dominant negative PDGF-C inhibits growth of Ewing family tumor cell lines.A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer.An essential role for senescent cells in optimal wound healing through secretion of PDGF-AAStretching fibroblasts remodels fibronectin and alters cancer cell migrationCRSBP-1/LYVE-l-null mice exhibit identifiable morphological and functional alterations of lymphatic capillary vessels.Intratumoral drug delivery with nanoparticulate carriers.Tyrosine kinases as targets in cancer therapy - successes and failures.Platelet-derived growth factor as a therapeutic target for systemic autoimmune diseases.STI571 as a targeted therapy for CML.Development and possible clinical use of antagonists for PDGF and TGF-beta.Tyrphostin AG 1296 induces glioblastoma cell apoptosis in vitro and in vivo.Characterization of the G-quadruplexes in the duplex nuclease hypersensitive element of the PDGF-A promoter and modulation of PDGF-A promoter activity by TMPyP4Stromal platelet-derived growth factor receptor α (PDGFRα) provides a therapeutic target independent of tumor cell PDGFRα expression in lung cancer xenografts.Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis.A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.Pharmacotherapy of acute lung injury and acute respiratory distress syndromeActivation of PDGFr-β Signaling Pathway after Imatinib and Radioimmunotherapy Treatment in Experimental Pancreatic Cancer.Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.Regulation of Platelet Derived Growth Factor Signaling by Leukocyte Common Antigen-related (LAR) Protein Tyrosine Phosphatase: A Quantitative Phosphoproteomics StudyMLLT11/AF1q boosts oncogenic STAT3 activity through Src-PDGFR tyrosine kinase signaling.Human airway smooth muscle cell proliferation from asthmatics is negatively regulated by semaphorin3A.Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.Autocrine PDGF stimulation in malignancies.Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells.Heat-shock protein 90 (Hsp90) as anticancer target for drug discovery: an ample computational perspective.Variability in Platelet-Derived Growth Factor Receptor Alpha Antibody Specificity May Impact Clinical Utility of Immunohistochemistry Assays.Drug Monographs: Olaratumab and Rucaparib.STXBP4 Drives Tumor Growth and Is Associated with Poor Prognosis through PDGF Receptor Signaling in Lung Squamous Cell Carcinoma.Nilotinib attenuates endothelial dysfunction and liver damage in high-cholesterol-fed rabbits.Suppression of cellular invasion by glybenclamide through inhibited secretion of platelet-derived growth factor in ovarian clear cell carcinoma ES-2 cells.Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge.
P2860
Q27675037-099F3C18-4B0C-46B1-8B4E-49C61B87060AQ28741084-DECDCEA2-0B8E-4312-B879-F1EA074C07F1Q30492863-A6B68AB0-4B3A-4015-B452-EE612D4395F2Q30842488-39E7A536-A340-43FA-BBA8-4A9C3EDF29CDQ30854890-6E92D53B-F780-4720-BCE7-0CFE434960E6Q33322533-A53D10F7-58EC-42ED-8F83-D3BF1A072518Q33574341-76C35A30-D836-4369-8666-6AF99E254675Q33625089-79949CFC-75D5-422A-A26A-CFD0D3788A1EQ34046989-5DFB8B1B-62E8-474B-B770-347AEC541CEDQ34130448-983E1593-8F58-4FFE-BFC4-A633F580C3D3Q34433040-0537E0FB-C5EE-4117-BF54-81AFFE25F94CQ34453396-7E0AFCF5-8C83-45EC-A4F0-094AAACEE54DQ35062322-64592E17-60FF-42AE-9357-766756B94106Q35073422-3C379331-C548-4979-8217-8984D6AB079EQ35091415-A8556FA1-DF4D-4EEF-8D3A-2A294653C93FQ35095147-75CA07BC-27CF-496E-967E-CE716BE4764EQ35161761-B7C63C8B-91D8-4288-8E23-4C8B94585860Q35193288-AEDC6C89-02AB-4076-86B4-D92ACB357B72Q35929445-FB4546D5-C5D3-4944-A1C8-685E23E0223DQ36334429-67FA2D27-A5E2-40A5-B5D0-90622E030A1FQ36360588-FE2E37E6-EB4A-407C-8B9D-BBC60B55D5AFQ36392642-9D0E1CAF-9A37-44EA-9CDA-473D30BDF885Q36403334-A7B520E2-0756-4FDF-8D5D-1180CE686D92Q36610713-48F56AD6-1A6B-41A0-8F99-9C34562FCF83Q37085611-8D438ADD-F4AF-4B5A-A2BE-177DC032D5EAQ37132792-B91C77E5-6158-459B-963D-EA4381F2BCE5Q37247964-B4DF3273-DFBE-4192-87CA-9CCC8D0A1538Q37372330-923949D2-3617-4475-AB7A-150A8E5E5549Q37536748-60C04B96-5771-49A7-99BB-855A87BC71ACQ37696987-204745A3-7EB8-4B99-A818-DEB17F39C859Q37761374-D8840BA5-D844-4F19-8610-699C7479685CQ38003387-B2083069-8367-4DFD-9CFE-D3B0DF85DC57Q38452580-3CE6654E-9023-475D-8C33-1A7ED82C0FDEQ38469746-508549CE-72D3-429A-9FAA-7A10B8FC135DQ38731617-659EF001-1D45-4220-8194-0F7CA3642F4CQ38779989-B86515D8-F789-4A78-92FD-3B0B9A398790Q39021056-06C07BAA-27F1-4C7B-924B-B0BADC068AF4Q39110979-E270F433-763E-4B36-B67E-F0C3CFDB8397Q39335926-E219B3F8-519A-4F76-A3A2-68E7FB564541Q41853921-30370A92-93F4-4FF1-8736-585B843D00F8
P2860
Involvement of platelet-derived growth factor in disease: development of specific antagonists.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Involvement of platelet-derive ...... pment of specific antagonists.
@ast
Involvement of platelet-derive ...... pment of specific antagonists.
@en
type
label
Involvement of platelet-derive ...... pment of specific antagonists.
@ast
Involvement of platelet-derive ...... pment of specific antagonists.
@en
prefLabel
Involvement of platelet-derive ...... pment of specific antagonists.
@ast
Involvement of platelet-derive ...... pment of specific antagonists.
@en
P1476
Involvement of platelet-derive ...... pment of specific antagonists.
@en
P2093
P356
10.1016/S0065-230X(01)80010-5
P577
2001-01-01T00:00:00Z